Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Syndax Pharmaceuticals Inc (SNDX) reports robust financials and strategic milestones, including FDA approvals and a ...

SEONGNAM, South Korea-- ( BUSINESS WIRE )--Qurient Co. Ltd. (KRX: 115180) has announced the commencement of a clinical trial ...

1. Niktimvo (anti-CSF1R): Approved for cGVHD, with commercial launch imminent. 2. Revumenib (menin inhibitor): In late-stage development for AML, with a PDUFA date set for December 26, 2024.

The company has an inhibitor of CSF1R – vimseltinib – which is due to start a phase 1/2 trial in tenoysynovial giant cell tumour (TGCT) before the end of the year. Other early-stage programmes ...

Targeting TAMs’ inflammatory signaling pathways, such as the CSF1R pathway, is a current research focus (52). Additionally, TAMs express immune checkpoint ligands, suggesting that lymphocyte-targeting ...

Abundant ligand–receptor-paired interactions were found between this microglia cluster and DR-enriched ECs. Notably, the CSF1/CSF1R signaling pathway was discovered between microglia and ECs, leading ...

Treatment with a compound that suppressed a receptor called CSF1R improved the transplantation efficiency of myeloid cells… The use of obesity medications — approved drugs for treating ...